Australian biotech giant CSL reported a 184 percent drop in net profit in the 2026 financial year, amid restructuring and lower flu vaccination rates in the United States.
During the year, the company reported total revenue of US$15.8 billion (down 1 percent) and a net profit after tax and amortisation (NPATA) of US$3.1 billion (down 2 percent).
However, one-off restructuring costs and impairments resulted in a net loss after tax of US$2.6 billion.
CSL’s vaccine division Sequirus reported an 8 percent drop in revenue to US$2 billion, partly reflecting the absence of non-recurring avian influenza revenue from the prior year.
Despite falling U.S. vaccination rates, the company said its worldwide seasonal influenza sales increased. …